Transglutaminase 2: A new paradigm for NF-κB involvement in disease

Advances in Enzymology and Related Areas of Molecular Biology

Volumn 78 1, Issue , 2011, Pages 161-195

  Kim, Soo Youl ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ANIMAL; BIOLOGICAL MODEL; DISEASES; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THEORETICAL MODEL;

ANIMALS; DISEASE; GTP-BINDING PROTEINS; HUMANS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES;

EID: 84863046220     PISSN: 0065258X     EISSN: None     Source Type: Book Series    
DOI: 10.1002/9781118105771.ch4     Document Type: Article

References (163)

1. Iismaa, S. E., Mearns, B. M., Lorand, L., and Graham, R. M. (2009) Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders, Physiol. Rev. 89, 991-1023.
2. Kim, S. Y. (2006) Transglutaminase 2 in inflammation, Front. Biosci. 11, 3026-3035.
3. Lee, J., Kim, Y. S., Choi, D. H., Bang, M. S., Han, T. R., Joh, T. H., and Kim, S. Y. (2004) Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia, J. Biol. Chem. 279, 53725-53735.
4. Kim, J. M., Voll, R. E., Ko, C., Kim, D. S., Park, K. S., and Kim, S. Y. (2008) A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells, J. Mol. Biol. 384, 756-765.
5. Park, S. S., Kim, J. M., Kim, D. S., Kim, I. H., and Kim, S. Y. (2006) Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster, J. Biol. Chem. 281, 34965-34972.
6. Kim, D. S., Park, S. S., Nam, B. H., Kim, I. H., and Kim, S. Y. (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation, Cancer Res. 66, 10936-10943.
7. Sohn, J., Kim, T. I., Yoon, Y. H., Kim, J. Y., and Kim, S. Y. (2003) Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis, J. Clin. Invest. 111, 121-128.
8. Cho, B. R., Kim, M. K., Suh, D. H., Hahn, J. H., Lee, B. G., Choi, Y. C., Kwon, T. J., Kim, S. Y., and Kim, D. J. (2008) Increased tissue transglutaminase expression in human atherosclerotic coronary arteries, Coron. Artery Dis. 19, 459-468.
9. Roberts, E. S., Zandonatti, M. A., Watry, D. D., Madden, L. J., Henriksen, S. J., Taffe, M. A., and Fox, H. S. (2003) Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS, Am. J. Pathol. 162, 2041-2057.
10. Park, K. C., Chung, K. C., Kim, Y. S., Lee, J., Joh, T. H., and Kim, S. Y. (2004) Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia, Biochem. Biophys. Res. Commun. 323, 1055-1062.
11. Ientile, R., Caccamo, D., and Griffin, M. (2007) Tissue transglutaminase and the stress response, Amino Acids 33, 385-394.
12. Park, K. S., Kim, H. K., Lee, J. H., Choi, Y. B., Park, S. Y., Yang, S. H., Kim, S. Y., and Hong, K. M. (2009) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer, J. Cancer Res. Clin. Oncol. 136(4), 493-502.
13. Ai, L., Kim,W. J., Demircan, B., Dyer, L.M., Bray, K. J., Skehan, R. R., Massoll, N. A., and Brown, K. D. (2008) The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer, Carcinogenesis 29, 510-518.
14. Maiuri, L., Luciani, A., Giardino, I., Raia, V., Villella, V. R., D'Apolito, M., Pettoello-Mantovani, M., Guido, S., Ciacci, C., Cimmino, M., Cexus, O. N., Londei, M., and Quaratino, S. (2008) Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation, J. Immunol. 180, 7697-7705.
15. Liu, S., Cerione, R. A., and Clardy, J. (2002) Structural basis for the guanine nucleotidebinding activity of tissue transglutaminase and its regulation of transamidation activity, Proc. Natl. Acad. Sci. U.S.A. 99, 2743-2747.
16. Begg, G. E., Carrington, L., Stokes, P. H., Matthews, J. M.,Wouters, M. A., Husain, A., Lorand, L., Iismaa, S. E., and Graham, R.M. (2006) Mechanism of allosteric regulation of transglutaminase 2 by GTP, Proc. Natl. Acad. Sci. U.S.A. 103, 19683-19688.
17. Siegel, M., Strnad, P., Watts, R. E., Choi, K., Jabri, B., Omary, M. B., and Khosla, C. (2008) Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury, PLoS One 3, e1861.
18. Haroon, Z. A., Hettasch, J. M., Lai, T. S., Dewhirst, M.W., and Greenberg, C. S. (1999) Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis, FASEB J. 13, 1787-1795.
19. Tatsukawa, H., Fukaya, Y., Frampton, G., Martinez-Fuentes, A., Suzuki, K., Kuo, T. F., Nagatsuma, K., Shimokado, K., Okuno, M.,Wu, J., Iismaa, S., Matsuura, T., Tsukamoto, H., Zern, M. A., Graham, R. M., and Kojima, S. (2009) Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1, Gastroenterology 136, 1783-1795 e1710.
20. Mirza, A., Liu, S. L., Frizell, E., Zhu, J., Maddukuri, S., Martinez, J., Davies, P., Schwarting, R., Norton, P., and Zern, M. A. (1997) A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB, Am. J. Physiol. 272, G281-G288.
21. Dvorak, C.M., Hardstedt, M., Xie, H.,Wang, M., Papas, K. K., Hering, B. J.,Murtaugh, M. P., and Fahrenkrug, S. C. (2007) Transcriptional profiling of stress response in cultured porcine islets, Biochem. Biophys. Res. Commun. 357, 118-125.
22. Luciani, A., Villella, V. R., Vasaturo, A., Giardino, I., Raia, V., Pettoello-Mantovani,M., D'Apolito,M., Guido, S., Leal, T., Quaratino, S., andMaiuri, L. (2009) SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation, J. Immunol. 183, 2775-2784.
23. Cacciamani, T., Virgili, S., Centurelli, M., Bertoli, E., Eremenko, T., and Volpe, P. (2002) Specific methylation of the CpG-rich domains in the promoter of the human tissue transglutaminase gene, Gene 297, 103-112.
24. Schuppan, D., Junker, Y., and Barisani, D. (2009) Celiac disease: from pathogenesis to novel therapies, Gastroenterology 137(6), 1912-1933.
25. Leeds, J. S., Horoldt, B. S., Sidhu, R., Hopper, A. D., Robinson, K., Toulson, B., Dixon, L., Lobo, A. J., McAlindon, M. E., Hurlstone, D. P., and Sanders, D. S. (2007) Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls, Scand. J. Gastroenterol. 42, 1214-1220.
26. Dieterich,W., Ehnis, T., Bauer,M., Donner, P., Volta, U., Riecken, E. O., and Schuppan, D. (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease, Nat. Med. 3, 797-801.
27. Arentz-Hansen, H., Korner, R., Molberg, O., Quarsten, H., Vader, W., Kooy, Y. M., Lundin, K. E., Koning, F., Roepstorff, P., Sollid, L. M., and McAdam, S. N. (2000) The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase, J. Exp. Med. 191, 603-612.
28. Molberg, O., McAdam, S. N., Korner, R., Quarsten, H., Kristiansen, C., Madsen, L., Fugger, L., Scott, H., Noren, O., Roepstorff, P., Lundin, K. E., Sjostrom, H., and Sollid, L. M. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease, Nat. Med. 4, 713-717.
29. Van De Wal, Y., Kooy, Y., Van Veelen, P., Pena, S., Mearin, L., Papadopoulos, G., and Koning, F. (1998) Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity, J. Immunol. 161, 1585-1588.
30. Sollid, L. M., Molberg, O., McAdam, S., and Lundin, K. E. (1997) Autoantibodies in coeliac disease: tissue transglutaminase-guilt by association?, Gut 41, 851-852.
31. Bruce, S. E., Bjarnason, I., and Peters, T. J. (1985) Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease, Clin. Sci. (Lond.) 68, 573-579.
32. Nilsen, E. M., Jahnsen, F. L., Lundin, K. E., Johansen, F. E., Fausa, O., Sollid, L. M., Jahnsen, J., Scott, H., and Brandtzaeg, P. (1998) Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease, Gastroenterology 115, 551-563.
33. Kim, S. Y., Jeong, E. J., and Steinert, P. M. (2002) IFN-gamma induces transglutaminase 2 expression in rat small intestinal cells, J. Interferon Cytokine Res. 22, 677-682.
34. Novogrodsky, A., Quittner, S., Rubin, A. L., and Stenzel, K. H. (1978) Transglutaminase activity in human lymphocytes: early activation by phytomitogens, Proc. Natl. Acad. Sci. U.S.A. 75, 1157-1161.
35. Schroff, G., Neumann, C., and Sorg, C. (1981) Transglutaminase as a marker for subsets of murine macrophages, Eur. J. Immunol. 11, 637-642.
36. Murtaugh, M. P., Mehta, K., Johnson, J., Myers, M., Juliano, R. L., and Davies, P. J. (1983) Induction of tissue transglutaminase in mouse peritoneal macrophages, J. Biol. Chem. 258, 11074-11081.
37. Murtaugh, M. P., Arend,W. P., and Davies, P. J. (1984) Induction of tissue transglutaminase in human peripheral blood monocytes, J. Exp. Med. 159, 114-125.
38. Seiving, B., Ohlsson, K., Linder, C., and Stenberg, P. (1991) Transglutaminase differentiation during maturation of human blood monocytes to macrophages, Eur. J. Haematol. 46, 263-271.
39. Cohen, J. (2002) The immunopathogenesis of sepsis, Nature 420, 885-891.
40. Hotchkiss, R. S. and Karl, I. E. (2003) The pathophysiology and treatment of sepsis, N. Engl. J. Med. 348, 138-150.
41. Leu, R. W., Herriott, M. J., Moore, P. E., Orr, G. R., and Birckbichler, P. J. (1982) Enhanced transglutaminase activity associated with macrophage activation. Possible role in Fc-mediated phagocytosis, Exp. Cell Res. 141, 191-199.
42. Bowness, J. M. and Tarr, A. H. (1997) Increase in transglutaminase and its extracellular products in response to an inflammatory stimulus by lipopolysaccharide, Mol. Cell. Biochem. 169, 157-163.
43. Suh, G. Y., Ham, H. S., Lee, S. H., Choi, J. C., Koh, W. J., Kim, S. Y., Lee, J., Han, J., Kim, H. P., Choi, A. M., and Kwon, O. J. (2006) A Peptide with anti-transglutaminase activity decreases lipopolysaccharide-induced lung inflammation in mice, Exp. Lung Res. 32, 43-53.
44. Falasca, L., Farrace, M. G., Rinaldi, A., Tuosto, L., Melino, G., and Piacentini, M. (2008) Transglutaminase type II is involved in the pathogenesis of endotoxic shock, J. Immunol. 180, 2616-2624.
45. Joneja, J. M.V. and Bielory, L. (1990) Understanding Allergy, Sensitivity, and Immunity: A Comprehensive Guide. Rutgers University Press, New Brunswick, pp. 126-136.
46. Chae, J. B., Lee, S., Kim, S. Y., Kim, J. G., and Yoon, Y. H. (2005) Novel transglutaminase inhibitors ameliorates endotoxininduced uveitis (EIU), J. Korean Ophthalmol. Soc. (Suppl. 46), 96.
47. Moreno, J. J. (2006) Effects of antiflammins on transglutaminase and phospholipase A2 activation by transglutaminase, Int. Immunopharmacol. 6, 300-303.
48. Choi, K., Siegel, M., Piper, J. L., Yuan, L., Cho, E., Strnad, P., Omary, B., Rich, K. M., and Khosla, C. (2005) Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2, Chem. Biol. 12, 469-475.
49. Kim, D. S., Park, K. S., Jeong, K. C., Lee, B. I., Lee, C. H., and Kim, S. Y. (2009) Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition, Cancer Lett. 273, 243-249.
50. Jeong, K. C., Ahn, K. O., Lee, B. I., Lee, C. H., and Kim, S. Y. (2009) The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible antiinflammatory effect through transglutaminase inhibition, J. Cancer Res. Clin. Oncol. 136(1), 143-150.
51. Rottner, M., Freyssinet, J. M., and Martinez, M. C. (2009) Mechanisms of the noxious inflammatory cycle in cystic fibrosis, Respir. Res. 10, 23.
52. Rommens, J. M., et al. (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping, Science 245, 1059-1065.
53. Kerem, B., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., and Tsui, L. C. (1989) Identification of the cystic fibrosis gene: genetic analysis, Science 245, 1073-1080.
54. Riordan, J. R., et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Science 245, 1066-1073.
55. Weber, A. J., Soong, G., Bryan, R., Saba, S., and Prince, A. (2001) Activation of NFkappaB in airway epithelial cells is dependent on CFTR trafficking and Cl-channel function, Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L71-L78.
56. Bright, J. J., Kanakasabai, S., Chearwae,W., and Chakraborty, S. (2008) PPARregulation of inflammatory signaling in CNS diseases, PPAR Res. 2008, 658520.
57. Grenard, P., Bresson-Hadni, S., El Alaoui, S., Chevallier,M., Vuitton, D. A., and Ricard-Blum, S. (2001) Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis, J. Hepatol. 35, 367-375.
58. Heyninck, K., Wullaert, A., and Beyaert, R. (2003) Nuclear factor-kappa B plays a central role in tumour necrosis factor-mediated liver disease, Biochem. Pharmacol. 66, 1409-1415.
59. Campo, G. M., Avenoso, A., Campo, S., Nastasi, G., Traina, P., D'Ascola, A., Rugolo, C. A., and Calatroni, A. (2008) The antioxidant activity of chondroitin-4-sulphate, in carbon tetrachloride-induced acute hepatitis in mice, involves NF-kappaB and caspase activation, Br. J. Pharmacol. 155, 945-956.
60. Johnson, T. S., El-Koraie, A. F., Skill, N. J., Baddour, N. M., El Nahas, A. M., Njloma, M., Adam, A. G., and Griffin, M. (2003) Tissue transglutaminase and the progression of human renal scarring, J. Am. Soc. Nephrol. 14, 2052-2062.
61. Lee, Z. W., Kwon, S. M., Kim, S. W., Yi, S. J., Kim, Y. M., and Ha, K. S. (2003) Activation of in situ tissue transglutaminase by intracellular reactive oxygen species, Biochem. Biophys. Res. Commun. 305, 633-640.
62. Curro, M., Condello, S., Caccamo, D., Ferlazzo, N., Parisi, G., and Ientile, R. (2009) Homocysteine-induced toxicity increases TG2 expression in Neuro2a cells, Amino Acids 36, 725-730.
63. Aeschlimann, D. and Thomazy, V. (2000) Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases, Connect. Tissue Res. 41, 1-27.
64. Nardacci, R., Lo Iacono, O., Ciccosanti, F., Falasca, L., Addesso, M., Amendola, A., Antonucci, G., Craxi, A., Fimia, G. M., Iadevaia, V., Melino, G., Ruco, L., Tocci, G., Ippolito, G., and Piacentini, M. (2003) Transglutaminase type II plays a protective role in hepatic injury, Am. J. Pathol. 162, 1293-1303.
65. Sun, B. and Karin, M. (2008) NF-kappaB signaling, liver disease and hepatoprotective agents, Oncogene 27, 6228-6244.
66. Joyce, M. A., Walters, K. A., Lamb, S. E., Yeh, M. M., Zhu, L. F., Kneteman, N., Doyle, J. S., Katze, M. G., and Tyrrell, D. L. (2009) HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice, PLoS Pathog. 5, e1000291.
67. Zhang, Y. L., Guo, Y. J., Bin, L., and Sun, S. H. (2009) Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7, J. Hepatol. 51, 29-38.
68. Wang, Q., Nagarkar, D. R., Bowman, E. R., Schneider, D., Gosangi, B., Lei, J., Zhao, Y., McHenry, C. L., Burgens, R. V., Miller, D. J., Sajjan, U., and Hershenson, M. B. (2009) Role of double-stranded RNApattern recognition receptors in rhinovirus-induced airway epithelial cell responses, J. Immunol. 183, 6989-6997.
69. Chen, C. S., Wu, C. H., Lai, Y. C., Lee, W. S., Chen, H. M., Chen, R. J., Chen, L. C., Ho, Y. S., andWang, Y. J. (2008) NF-kappaB-activated tissue transglutaminase is involved in ethanol-induced hepatic injury and the possible role of propolis in preventing fibrogenesis, Toxicology 246, 148-157.
70. Han, J. A. and Park, S. C. (2000) Transglutaminase-dependent modulation of transcription factor Sp1 activity, Mol. Cells 10, 612-618.
71. Denk, H., Gschnait, F., and Wolff, K. (1975) Hepatocellar hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation, Lab. Invest. 32, 773-776.
72. Yokoo, H., Harwood, T. R., Racker, D., and Arak, S. (1982) Experimental production of Mallory bodies in mice by diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine, Gastroenterology 83, 109-113.
73. Tazawa, J., Irie, T., and French, S. W. (1983) Mallory body formation runs parallel to gamma-glutamyl transferase induction in hepatocytes of griseofulvin-fed mice, Hepatology 3, 989-1001.
74. Denk, H., Bernklau, G., and Krepler, R. (1984) Effect of griseofulvin treatment and neoplastic transformation on transglutaminase activity in mouse liver, Liver 4, 208-213.
75. Riley, N. E., Li, J., Worrall, S., Rothnagel, J. A., Swagell, C., Van Leeuwen, F. W., and French, S. W. (2002) The Mallory body as an aggresome: in vitro studies, Exp. Mol. Pathol. 72, 17-23.
76. Zatloukal, K., Denk, H., Lackinger, E., and Rainer, I. (1989) Hepatocellular cytokeratins as substrates of transglutaminases, Lab. Invest. 61, 603-608.
77. Cadrin,M., Marceau, N., and French, S.W. (1992) Cytokeratin of apparent high molecular weight in livers from griseofulvin-fed mice, J. Hepatol. 14, 226-231.
78. Strnad, P., Siegel, M., Toivola, D. M., Choi, K., Kosek, J. C., Khosla, C., and Omary, M. B. (2006) Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation, FEBS Lett. 580, 2351-2357.
79. Tatsukawa, H., Fukaya, Y., Frampton, G., Martinez-Fuentes, A., Suzuki, K., Kuo, T. F., Nagatsuma, K., Shimokado, K., Okuno, M., Wu, J., Iismaa, S., Matsuura, T., Tsukamoto, H., Zern, M. A., Graham, R. M., and Kojima, S. (2009) Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1, Gastroenterology 136, 1783-1795 e1710.
80. Nan, L.,Wu, Y., Bardag-Gorce, F., Li, J., French, B. A.,Wilson, L. T., and French, S.W. (2005) The p105/50 NF-kappaB pathway is essential for Mallory body formation, Exp. Mol. Pathol. 78, 198-206.
81. Meguid El Nahas, A., and Bello, A. K. (2005) Chronic kidney disease: the global challenge, Lancet 365, 331-340.
82. Henke, N., Schmidt-Ullrich, R., Dechend, R., Park, J. K., Qadri, F., Wellner, M., Obst, M., Gross, V., Dietz, R., Luft, F. C., Scheidereit, C., and Muller, D. N. (2007) Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage, Circ. Res. 101, 268-276.
83. Johnson, T. S., Griffin, M., Thomas, G. L., Skill, J., Cox, A., Yang, B., Nicholas, B., Birckbichler, P. J., Muchaneta-Kubara, C., and Meguid El Nahas, A. (1997) The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis, J. Clin. Invest. 99, 2950-2960.
84. Chen, D., Huang, H. C., and Yu, L. (2005) Expression and implication of tissue transglutaminase and connective tissue growth factor at fibrotic tubulointerstitium in kidneys from UUO rats, Beijing Da Xue Xue Bao 37, 143-146.
85. Johnson, T. S., Fisher,M., Haylor, J. L., Hau, Z., Skill, N. J., Jones, R., Saint, R., Coutts, I., Vickers, M. E., El Nahas, A. M., and Griffin, M. (2007) Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease, J. Am. Soc. Nephrol. 18, 3078-3088.
86. Johnson, T. S., Abo-Zenah, H., Skill, J. N., Bex, S., Wild, G., Brown, C. B., Griffin, M., and El Nahas, A. M. (2004) Tissue transglutaminase: a mediator and predictor of chronic allograft nephropathy? Transplantation 77, 1667-1675.
87. Ikee, R., Kobayashi, S., Hemmi, N., Saigusa, T., Namikoshi, T., Yamada, M., Imakiire, T., Kikuchi, Y., Suzuki, S., and Miura, S. (2007) Involvement of transglutaminase-2 in pathological changes in renal disease, Nephron Clin Pract 105, c139-c146.
88. Parving, H. H. (2001) Diabetic nephropathy: prevention and treatment, Kidney Int 60, 2041-2055.
89. Remuzzi, G., Schieppati, A., and Ruggenenti, P. (2002) Clinical practice. Nephropathy in patients with type 2 diabetes, N. Engl. J. Med. 346, 1145-1151.
90. Skill, N. J., Griffin, M., El Nahas, A.M., Sanai, T., Haylor, J. L., Fisher, M., Jamie, M. F., Mould, N. N., and Johnson, T. S. (2001) Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications, Lab. Invest. 81, 705-716.
91. El Nahas, A. M., Abo-Zenah, H., Skill, N. J., Bex, S.,Wild, G., Griffin,M., and Johnson, T. S. (2004) Elevated epsilon-(gamma-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase, Nephron Clin Pract 97, c108-c117.
92. Huang, L., Haylor, J. L., Hau, Z., Jones, R. A., Vickers, M. E., Wagner, B., Griffin, M., Saint, R. E., Coutts, I. G., El Nahas, A. M., and Johnson, T. S. (2009) Transglutaminase inhibition ameliorates experimental diabetic nephropathy, Kidney Int. 76, 383-394.
93. Shweke, N., Boulos, N., Jouanneau, C., Vandermeersch, S., Melino, G., Dussaule, J. C., Chatziantoniou, C.,Ronco, P., and Boffa, J. J. (2008) Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGFbeta activation and cell infiltration, Am. J. Pathol. 173, 631-642.
94. Shimizu, K., Mitchell, R. N., and Libby, P. (2006) Inflammation and cellular immune responses in abdominal aortic aneurysms, Arterioscler. Thromb. Vasc. Biol. 26, 987-994.
95. Barath, P., Fishbein, M. C., Cao, J., Berenson, J., Helfant, R. H., and Forrester, J. S. (1990) Detection and localization of tumor necrosis factor in human atheroma, Am. J. Cardiol. 65, 297-302.
96. Brand, K., Page, S., Walli, A. K., Neumeier, D., and Baeuerle, P. A. (1997) Role of nuclear factor-kappa B in atherogenesis, Exp. Physiol. 82, 297-304.
97. de Winther, M. P., Kanters, E., Kraal, G., and Hofker, M. H. (2005) Nuclear factor kappaB signaling in atherogenesis, Arterioscler. Thromb. Vasc. Biol. 25, 904-914.
98. Collins, T. and Cybulsky, M. I. (2001) NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest. 107, 255-264.
99. Brand, K., Eisele, T.,Kreusel, U., Page,M., Page, S., Haas,M., Gerling, A., Kaltschmidt, C., Neumann, F. J.,Mackman, N., Baeurele, P. A.,Walli, A. K., and Neumeier, D. (1997) Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein, Arterioscler. Thromb. Vasc. Biol. 17, 1901-1909.
100. Cercek, B., Yamashita, M., Dimayuga, P., Zhu, J., Fishbein, M. C., Kaul, S., Shah, P. K., Nilsson, J., and Regnstrom, J. (1997) Nuclear factor-kappaB activity and arterial response to balloon injury, Atherosclerosis 131, 59-66.
101. Lindner, V. (1998) The NF-kappaB and IkappaB system in injured arteries, Pathobiology 66, 311-320.
102. Landry, D. B., Couper, L. L., Bryant, S. R., and Lindner, V. (1997) Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1, Am. J. Pathol. 151, 1085-1095.
103. Bryant, S. R., Bjercke, R. J., Erichsen, D. A., Rege, A., and Lindner, V. (1999) Vascular remodeling in response to altered blood flow is mediated by fibroblast growth factor-2, Circ. Res. 84, 323-328.
104. Squadrito, F., Deodato, B., Bova, A., Marini, H., Saporito, F., Calo, M., Giacca, M., Minutoli, L., Venuti, F. S., Caputi, A. P., and Altavilla, D. (2003) Crucial role of nuclear factor-kappaB in neointimal hyperplasia of the mouse carotid artery after interruption of blood flow, Atherosclerosis 166, 233-242.
105. Freund, C., Schmidt-Ullrich, R., Baurand, A., Dunger, S., Schneider, W., Loser, P., El-Jamali, A., Dietz, R., Scheidereit, C., and Bergmann, M. W. (2005) Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo, Circulation 111, 2319-2325.
106. Herrmann, O., Baumann, B., De Lorenzi, R., Muhammad, S., Zhang, W., Kleesiek, J., Malfertheiner, M., Kohrmann, M., Potrovita, I., Maegele, I., Beyer, C., Burke, J. R., Hasan, M. T., Bujard, H., Wirth, T., Pasparakis, M., and Schwaninger, M. (2005) IKK mediates ischemia-induced neuronal death, Nat. Med. 11, 1322-1329.
107. Luedde, T., Assmus, U.,Wustefeld, T., Meyer zu Vilsendorf, A., Roskams, T., Schmidt-Supprian, M., Rajewsky, K., Brenner, D. A., Manns, M. P., Pasparakis, M., and Trautwein, C. (2005) Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury, J. Clin. Invest. 115, 849-859.
108. Muller, D. N., Heissmeyer, V., Dechend, R., Hampich, F., Park, J. K., Fiebeler, A., Shagdarsuren, E., Theuer, J., Elger, M., Pilz, B., Breu, V., Schroer, K., Ganten, D., Dietz, R., Haller, H., Scheidereit, C., and Luft, F. C. (2001) Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage, FASEB J. 15, 1822-1824.
109. Iwai, N., Shimoike, H., and Kinoshita, M. (1995) Genes up-regulated in hypertrophied ventricle, Biochem. Biophys. Res. Commun. 209, 527-534.
110. Boisvert,W. A., Rose, D.M., Boullier, A., Quehenberger, O., Sydlaske, A., Johnson, K. A., Curtiss, L. K., and Terkeltaub, R. (2006) Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size, Arterioscler. Thromb. Vasc. Biol. 26, 563-569.
111. Johnson, K. A., Polewski,M., and Terkeltaub, R. A. (2008) Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells,Circ. Res. 102, 529-537.
112. Tozawa, K., Yasui, T., Okada, A., Hirose, M., Hamamoto, S., Itoh, Y., and Kohri, K. (2008) NF-kappaB activation in renal tubular epithelial cells by oxalate stimulation, Int. J. Urol. 15, 924-928.
113. Attur, M. G., Patel, I. R., Patel, R. N., Abramson, S. B., and Amin,A.R. (1998) Autocrine production of IL-1 beta by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8, Proc. Assoc. Am. Physicians 110, 65-72.
114. Borzi, R. M., Mazzetti, I., Macor, S., Silvestri, T., Bassi, A., Cattini, L., and Facchini, A. (1999) Flow cytometric analysis of intracellular chemokines in chondrocytes in vivo: constitutive expression and enhancement in osteoarthritis and rheumatoid arthritis, FEBS Lett. 455, 238-242.
115. Olson, T. S. and Ley, K. (2002) Chemokines and chemokine receptors in leukocyte trafficking, Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R7-R28.
116. Merz, D., Liu, R., Johnson, K., and Terkeltaub, R. (2003) IL-8/CXCL8 and growthrelated oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation, J. Immunol. 171, 4406-4415.
117. Roman-Blas, J. A. and Jimenez, S. A. (2006) NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis, Osteoarthritis Cartilage 14, 839-848.
118. Pulai, J. I., Chen, H., Im, H. J., Kumar, S., Hanning, C., Hegde, P. S., and Loeser, R. F. (2005) NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments, J. Immunol. 174, 5781-5788.
119. Forsyth, C. B., Cole, A., Murphy, G., Bienias, J. L., Im, H. J., and Loeser, R. F., Jr. (2005) Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli, J. Gerontol. A Biol. Sci. Med. Sci. 60, 1118-1124.
120. Loeser, R. F., Yammani, R. R., Carlson, C. S., Chen, H., Cole, A., Im, H. J., Bursch, L. S., and Yan, S. D. (2005) Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis, Arthritis Rheum. 52, 2376-2385.
121. Johnson, K. A. and Terkeltaub, R. A. (2005) External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcification, J. Biol. Chem. 280, 15004-15012.
122. Lorand, L. and Graham, R. M. (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions, Nat. Rev. Mol. Cell Biol. 4, 140-156.
123. Zemskov, E. A., Janiak, A., Hang, J., Waghray, A., and Belkin, A. M. (2006) The role of tissue transglutaminase in cell-matrix interactions, Front. Biosci. 11, 1057-1076.
124. Johnson, K. A., van Etten, D., Nanda, N., Graham, R. M., and Terkeltaub, R. A. (2003) Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy, J. Biol. Chem. 278, 18824-18832.
125. Cecil, D. L. and Terkeltaub, R. (2008) Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes, J. Immunol. 180, 8378-8385.
126. Orlandi, A., Oliva, F., Taurisano, G., Candi, E., Di Lascio, A., Melino, G., Spagnoli, L. G., and Tarantino, U. (2009) Transglutaminase-2 differently regulates cartilage destruction and osteophyte formation in a surgical model of osteoarthritis, Amino Acids 36, 755-763.
127. Bakker, A. C., Van De Loo, F. A., van Beuningen, H. M., Sime, P., van Lent, P. L., Van Der Kraan, P. M., Richards, C. D., and Van Den Berg, W. B. (2001) Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation, Osteoarthritis Cartilage 9, 128-136.
128. Gouze, J. N., Bianchi, A., Becuwe, P., Dauca, M., Netter, P., Magdalou, J., Terlain, B., and Bordji, K. (2002) Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway, FEBS Lett. 510, 166-170.
129. Largo, R.,Alvarez-Soria, M. A., Diez-Ortego, I.,Calvo, E., Sanchez-Pernaute, O., Egido, J., and Herrero-Beaumont, G. (2003) Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes, Osteoarthritis Cartilage 11, 290-298.
130. Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression, Nature 441, 431-436.
131. Karin, M. (2008) The IkappaB kinase-a bridge between inflammation and cancer, Cell Res. 18, 334-342.
132. Nakanishi, C. and Toi, M. (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs, Nat. Rev. Cancer 5, 297-309.
133. Tergaonkar, V., Bottero, V., Ikawa, M., Li, Q., and Verma, I. M. (2003) IkappaB kinaseindependent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy, Mol. Cell Biol. 23, 8070-8083.
134. Pacifico, F. and Leonardi, A. (2006) NF-kappaB in solid tumors, Biochem. Pharmacol. 72, 1142-1152.
135. Mehta, K. (1994) High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells, Int. J. Cancer 58, 400-406.
136. Han, J. A. and Park, S. C. (1999) Hydrogen peroxide mediates doxorubicin-induced transglutaminase 2 expression in PC-14 human lung cancer cell line, Exp. Mol. Med. 31, 83-88.
137. Antonyak,M. A., Miller, A.M., Jansen, J.M., Boehm, J. E., Balkman, C. E.,Wakshlag, J. J., Page, R. L., and Cerione, R. A. (2004) Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells, J. Biol. Chem. 279, 41461-41467.
138. Yuan, L., Choi, K., Khosla, C., Zheng, X., Higashikubo, R., Chicoine, M. R., and Rich, K. M. (2005) Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas, Mol. Cancer Ther. 4, 1293-1302.
139. Yuan, L., Siegel, M., Choi, K., Khosla, C., Miller, C. R., Jackson, E. N., Piwnica-Worms, D., and Rich, K. M. (2007) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy, Oncogene 26, 2563-2573.
140. Hwang, J. Y., Mangala, L. S., Fok, J. Y., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Nick, A.M., Fiterman, D. J., Vivas-Mejia, P. E., Deavers,M. T., Coleman, R. L., Lopez-Berestein, G., Mehta, K., and Sood, A. K. (2008) Clinical and biological significance of tissue transglutaminase in ovarian carcinoma, Cancer Res. 68, 5849-5858.
141. Kim, D. S., Park, S. S., Nam, B. H., Kim, I. H., and Kim, S. Y. (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation, Cancer Res. 66, 10936-10943.
142. Kim, D. S., Park, K. S., and Kim, S. Y. (2009) Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors, Front. Biosci. 14, 2514-2521.
143. Muma, N. A. (2007) Transglutaminase is linked to neurodegenerative diseases, J. Neuropathol. Exp. Neurol. 66, 258-263.
144. Gilad, G. M. and Varon, L. E. (1985) Transglutaminase activity in rat brain: characterization, distribution, and changes with age, J. Neurochem. 45, 1522-1526.
145. Appelt, D. M., Kopen, G. C., Boyne, L. J., and Balin, B. J. (1996) Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease, J. Histochem. Cytochem. 44, 1421-1427.
146. Johnson, G. V., Cox, T. M., Lockhart, J. P., Zinnerman,M. D., Miller,M. L., and Powers, R. E. (1997) Transglutaminase activity is increased in Alzheimer's disease brain, Brain Res. 751, 323-329.
147. Lesort,M., Chun,W., Johnson, G. V., and Ferrante, R. J. (1999) Tissue transglutaminase is increased in Huntington's disease brain, J. Neurochem. 73, 2018-2027.
148. Kim, S. Y., Grant, P., Lee, J. H., Pant, H. C., and Steinert, P. M. (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease, J. Biol. Chem. 274, 30715-30721.
149. Junn, E., Ronchetti, R. D., Quezado, M. M., Kim, S. Y., and Mouradian, M. M. (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. U.S.A. 100, 2047-2052.
150. Karpuj, M. V., Garren, H., Slunt, H., Price, D. L., Gusella, J., Becher, M. W., and Steinman, L. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei, Proc. Natl. Acad. Sci. U.S.A. 96, 7388-7393.
151. Kim, S. Y., Marekov, L., Bubber, P., Browne, S. E., Stavrovskaya, I., Lee, J., Steinert, P. M., Blass, J. P., Beal, M. F., Gibson, G. E., and Cooper, A. J. (2005) Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain, Neurochem. Res. 30, 1245-1255.
152. Davis, D. G., Schmitt, F. A.,Wekstein, D. R., and Markesbery,W. R. (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects, J. Neuropathol. Exp. Neurol. 58, 376-388.
153. Morris, J. C. (1999) Is Alzheimer's disease inevitable with age?: Lessons from clinicopathologic studies of healthy aging and very mild alzheimer's disease, J. Clin. Invest. 104, 1171-1173.
154. Gonzalez-Scarano, F. and Martin-Garcia, J. (2005) The neuropathogenesis of AIDS, Nat. Rev. Immunol. 5, 69-81.
155. Wajgt, A. and Gorny, M. (1983) CSF antibodies to myelin basic protein and to myelinassociated glycoprotein in multiple sclerosis. Evidence of the intrathecal production of antibodies, Acta Neurol. Scand. 68, 337-343.
156. Selkoe, D. J., Abraham, C., and Ihara, Y. (1982) Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers, Proc. Natl. Acad. Sci. U.S.A. 79, 6070-6074.
157. Rostasy, K., Monti, L., Yiannoutsos, C., Wu, J., Bell, J., Hedreen, J., and Navia, B. A. (2000) NFkappaB activation, TNF-alpha expression, and apoptosis in the AIDSDementia-Complex, J. Neurovirol. 6, 537-543.
158. Caccamo, D., Campisi, A., Curro, M., Aguennouz, M., Li Volti, G., Avola, R., and Ientile, R. (2005) Nuclear factor-kappab activation is associated with glutamate-evoked tissue transglutaminase up-regulation in primary astrocyte cultures, J. Neurosci. Res. 82, 858-865.
159. Stormer, L. (1952) Phylogeny and taxonomy of fossil horseshoe crab, J. Paleontol. 26, 630-639.
160. Tokunaga, F., Muta, T., Iwanaga, S., Ichinose, A., Davie, E. W., Kuma, K., and Miyata, T. (1993) Limulus hemocyte transglutaminase. cDNA cloning, amino acid sequence, and tissue localization, J. Biol. Chem. 268, 262-268.
161. Fuller, G.M. and Doolittle, R. F. (1971) Studies of invertebrate fibrinogen. I. Purification and characterization of fibrinogen from the spiny lobster, Biochemistry 10, 1305-1311.
162. Okada, Y., Nagase, H., and Harris, E. D., Jr. (1986) A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization, J. Biol. Chem. 261, 14245-14255.
163. Park, K. S., Kim, D. S., Ko, C., Lee, S. J., Oh, S. H., and Kim, S. Y. (2011) TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2, Front Biosci (Elite Ed). 3, 341-354.